Median stimulated C-peptide concentrations decreased mildly in both groups by 12 months (by 20% in the placebo group and by 17% in the atorvastatin group, p<0.01 each).
Phospho-P70 decreased mildly (15 and 25%) after single-agent temsirolimus and the combined regimen, respectively.
In addition, home BP in the morning, which was measured within 1 h after waking as described previously [ 9, 10], decreased mildly.
During this normal developmental process, the content of sGAG decreased mildly as evidenced by the slightly decrease of safranin-O SI with age in control group by histology analysis.
The areal yield of VA-SWCNTs decreased drastically from 1.6 to 0.4 mg cm−2 for the first 4 substrates with 50 ppmv H2O because of its depletion whereas it decreased more mildly from 1.6 to 0.8 mg cm−2 for the whole 18 substrates with 1.0 vol% CO2.
First, regarding the target population, the severer the diseases are, the more benefits the patients tend to take from the therapy; if the LVEF decreased only mildly, the patient would not be able to expect much gain from the intervention.
The subjects were divided into two groups according to the rate of change in disc height: mildly decreased (≤20 % decrease) and severely decreased (>20 % decrease).
At baseline, patients had high mRss (median 30), a moderately decreased DLCO (median 62%), mildly decreased FVC (median 72%) and relatively early disease (median duration 20.5 months).
Serum Na+, Mg2+ and K+ levels were lowest in the elevated eGFR group (P < 0.01) and showed decreasing trends from the mildly decreased eGFR group, normal eGFR group to the elevated eGFR group (P < 0.01).
Comparing the eGFR groups (normal, mildly decreased, moderately decreased and severely decreased) gave a kappa of 0.60 (95% CI 0.59 0.60).
